Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer's disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders. The Company also focuses on developing nelotanserin, a selective 5-hydroxytryptamine 2A receptor inverse agonist, for the treatment of rapid eye movement (REM) behavior disorder (RBD) in DLB patients, and visual hallucinations in patients with Lewy body dementia. Its AXO-Lenti-PD is an in vivo lentiviral gene therapy investigational product candidate and being developed for the one-time treatment of Parkinson's disease.
View Top Employees from Axovant Sciences LtdWebsite | http://axovant.com |
Ticker | AXON |
Revenue | $18 million |
Funding | $370 million |
Employees | 41 (34 on RocketReach) |
Founded | 2014 |
Phone | +44 20 3997 8931 |
Industry | Pharmaceutical Manufacturing, Biotechnology, Pharmaceuticals, Healthcare, Drug Manufacturing & Research, Medical Testing & Clinical Laboratories |
Web Rank | 4 Million |
Keywords | Axovant Gene Therapies, Pharmaceutical Companies Ny, Axovant, New York City Pharmaceutical Companies, Heather Gray-Edwards, Phd, Dvm |
Competitors | Abeona Therapeutics, Adverum Biotechnologies, Curemark, LLC, Metacrine, Inc., TG Therapeutics, Inc. |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 325412 Companies, NAICS Code 32541 Companies, NAICS Code 3254 Companies, NAICS Code 32 Companies, NAICS Code 325 Companies |
Looking for a particular Axovant Sciences Ltd employee's phone or email?
The Axovant Sciences Ltd annual revenue was $18 million in 2023.
34 people are employed at Axovant Sciences Ltd.
The NAICS codes for Axovant Sciences Ltd are [325412, 32541, 3254, 32, 325].
The SIC codes for Axovant Sciences Ltd are [283, 28].